Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact
Launched by ABBVIE (PRIOR SPONSOR, ABBOTT) · Aug 30, 2005
Trial Information
Current as of May 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Advanced idiopathic Parkinson's disease
- Exclusion Criteria:
- • - Other diseases which might influence compliance or participation in the study
About Abbvie (Prior Sponsor, Abbott)
AbbVie is a global biopharmaceutical company formed in 2013 as a spinoff from Abbott Laboratories, focusing on the discovery, development, and commercialization of advanced therapies for complex diseases. With a commitment to innovation and patient-centric solutions, AbbVie leverages cutting-edge research and a robust pipeline to address unmet medical needs across various therapeutic areas, including immunology, oncology, and neuroscience. The company's dedication to advancing healthcare is underscored by its collaborative approach, engaging with healthcare professionals, patients, and stakeholders to deliver groundbreaking treatments that improve patient outcomes and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Lars Bergmann, MD
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials